274 related articles for article (PubMed ID: 12874383)
1. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.
Chen CH; Chernis GA; Hoang VQ; Landgraf R
Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9226-31. PubMed ID: 12874383
[TBL] [Abstract][Full Text] [Related]
2. A human epidermal growth factor receptor 3/heregulin interaction inhibitor aptamer discovered using SELEX.
Yokoyama T; Ando T; Iwamoto R; Fuji D; Yamamoto M; Kawakami T
Biochem Biophys Res Commun; 2021 May; 553():148-153. PubMed ID: 33770580
[TBL] [Abstract][Full Text] [Related]
3. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
[TBL] [Abstract][Full Text] [Related]
4. Distinct characteristics of heregulin signals mediated by HER3 or HER4.
Weiss FU; Wallasch C; Campiglio M; Issing W; Ullrich A
J Cell Physiol; 1997 Nov; 173(2):187-95. PubMed ID: 9365520
[TBL] [Abstract][Full Text] [Related]
5. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy.
Shi X; Xu L; Yu J; Fang X
Exp Cell Res; 2009 Oct; 315(16):2847-55. PubMed ID: 19497323
[TBL] [Abstract][Full Text] [Related]
6. Heregulin reverses the oligomerization of HER3.
Landgraf R; Eisenberg D
Biochemistry; 2000 Jul; 39(29):8503-11. PubMed ID: 10913256
[TBL] [Abstract][Full Text] [Related]
7. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
8. Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation.
De Potter IY; Poumay Y; Squillace KA; Pittelkow MR
Exp Cell Res; 2001 Dec; 271(2):315-28. PubMed ID: 11716544
[TBL] [Abstract][Full Text] [Related]
9. HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).
Sollome JJ; Thavathiru E; Camenisch TD; Vaillancourt RR
Cell Signal; 2014 Jan; 26(1):70-82. PubMed ID: 24036211
[TBL] [Abstract][Full Text] [Related]
10. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
Razumienko EJ; Scollard DA; Reilly RM
J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of EGFR family-mediated HRG signals in human ovarian cancer.
Campiglio M; Ali S; Knyazev PG; Ullrich A
J Cell Biochem; 1999 Jun; 73(4):522-32. PubMed ID: 10733345
[TBL] [Abstract][Full Text] [Related]
12. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
Lee H; Akita RW; Sliwkowski MX; Maihle NJ
Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
[TBL] [Abstract][Full Text] [Related]
13. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
[TBL] [Abstract][Full Text] [Related]
14. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
15. Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells.
Sepp-Lorenzino L; Eberhard I; Ma Z; Cho C; Serve H; Liu F; Rosen N; Lupu R
Oncogene; 1996 Apr; 12(8):1679-87. PubMed ID: 8622888
[TBL] [Abstract][Full Text] [Related]
16. A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.
Kim S; Han J; Shin I; Kil WH; Lee JE; Nam SJ
Exp Mol Med; 2012 Aug; 44(8):473-82. PubMed ID: 22627808
[TBL] [Abstract][Full Text] [Related]
17. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
Tan M; Grijalva R; Yu D
Cancer Res; 1999 Apr; 59(7):1620-5. PubMed ID: 10197638
[TBL] [Abstract][Full Text] [Related]
18. Identification of a heregulin binding site in HER3 extracellular domain.
Singer E; Landgraf R; Horan T; Slamon D; Eisenberg D
J Biol Chem; 2001 Nov; 276(47):44266-74. PubMed ID: 11555649
[TBL] [Abstract][Full Text] [Related]
19. The extracellular region of heregulin is sufficient to promote mammary gland proliferation and tumorigenesis but not apoptosis.
Weinstein EJ; Leder P
Cancer Res; 2000 Jul; 60(14):3856-61. PubMed ID: 10919660
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine phosphorylation of PYK2 mediates heregulin-induced glioma invasion: novel heregulin/HER3-stimulated signaling pathway in glioma.
van der Horst EH; Weber I; Ullrich A
Int J Cancer; 2005 Feb; 113(5):689-98. PubMed ID: 15499613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
